The vaccine will target a protein, alpha-lactalbumin, which is usually made in lactating breasts. There is no other time when normal human cells make that protein, except some 70% of triple-negative breast cancers make the protein, according to Dr. G. Thomas Budd, an oncologist at the Cleveland Clinic and principal investigator of the study.
"What we hope to do is, first, show that we can mount an immune response against one protein that is expressed in the majority of triple-negative breast cancer," said Budd."And if we can, we might be able to vaccinate patients or people who are at risk to develop breast cancer, and then prevent them from getting it in the first place — that's the long-term goal."
The 18-24 people in the trial will receive varying doses of the vaccine to determine the side effects and whether it produces the desired immunologic response. They'll receive three vaccinations, two weeks apart. The goal of the phase 1 study is determine what dose should be used in further studies, based on side effects and the immune response.
“This vaccine approach represents a potential new way to control breast cancer,” said Vincent Tuohy, the primary inventor of the vaccine and staff immunologist at Cleveland Clinic’s Lerner Research Institute, in a press release. “The long-term objective of this research is to determine if this vaccine can prevent breast cancer before it occurs, particularly the more aggressive forms of this disease that predominate in high-risk women.
Lets hope people don’t make this political like the Covid vaccine
This should go as fast as they pushed the COVID vaccine let’s get it done